Cargando…

Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy

INTRODUCTION: Cutaneous immune-related adverse-events (cIRAEs), commonly seen in cancer patients receiving immune checkpoint inhibitors (ICI) are reported to be associated with better patient survival; however, they have seldom been studied in Indian population. Recent reports suggest racial differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Duraisamy, Prasanna, Panicker, Vinitha Varghese, Jose, Wesley Mannirathil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412045/
https://www.ncbi.nlm.nih.gov/pubmed/37557151
http://dx.doi.org/10.5826/dpc.1303a127
_version_ 1785086798159937536
author Duraisamy, Prasanna
Panicker, Vinitha Varghese
Jose, Wesley Mannirathil
author_facet Duraisamy, Prasanna
Panicker, Vinitha Varghese
Jose, Wesley Mannirathil
author_sort Duraisamy, Prasanna
collection PubMed
description INTRODUCTION: Cutaneous immune-related adverse-events (cIRAEs), commonly seen in cancer patients receiving immune checkpoint inhibitors (ICI) are reported to be associated with better patient survival; however, they have seldom been studied in Indian population. Recent reports suggest racial differences in IRAEs and also in survival outcomes. OBJECTIVES: To study the various cIRAEs in Indian patients on ICI therapy and to analyze the association between cIRAEs and patient survival outcomes. METHODS: We conducted a retrospective cohort study of 86 cancer patients receiving immunotherapies in a tertiary care hospital in India and studied incidence, nature and grades of cutaneous immune-related adverse events and the association of cIRAEs with the patient survival outcomes. RESULTS: Eighty-six patients were included, of whom 16 patients (18.6%) developed cIRAEs, with pruritus (12.8%) and maculopapular eruption (8.1%) being the most common. Kaplan–Meier plot with log-rank test showed that patients developing any type of cIRAE had longer progression-free survival than those without (P = 0.023) and a better objective-response-rate (50% versus 18.5%, P = 0.008). CONCLUSIONS: Most common cIRAEs in our study were pruritus and maculopapular rash. The incidence of cIRAEs was lower in our Indian cohort compared to that reported in Caucasian cohorts. Development of cutaneous immune-related adverse event in cancer patients on ICI was associated with a longer progression-free-survival and a better objective-response-rate. Thus, cIRAEs may serve as a surrogate marker for better patient outcomes.
format Online
Article
Text
id pubmed-10412045
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-104120452023-08-10 Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy Duraisamy, Prasanna Panicker, Vinitha Varghese Jose, Wesley Mannirathil Dermatol Pract Concept Original Article INTRODUCTION: Cutaneous immune-related adverse-events (cIRAEs), commonly seen in cancer patients receiving immune checkpoint inhibitors (ICI) are reported to be associated with better patient survival; however, they have seldom been studied in Indian population. Recent reports suggest racial differences in IRAEs and also in survival outcomes. OBJECTIVES: To study the various cIRAEs in Indian patients on ICI therapy and to analyze the association between cIRAEs and patient survival outcomes. METHODS: We conducted a retrospective cohort study of 86 cancer patients receiving immunotherapies in a tertiary care hospital in India and studied incidence, nature and grades of cutaneous immune-related adverse events and the association of cIRAEs with the patient survival outcomes. RESULTS: Eighty-six patients were included, of whom 16 patients (18.6%) developed cIRAEs, with pruritus (12.8%) and maculopapular eruption (8.1%) being the most common. Kaplan–Meier plot with log-rank test showed that patients developing any type of cIRAE had longer progression-free survival than those without (P = 0.023) and a better objective-response-rate (50% versus 18.5%, P = 0.008). CONCLUSIONS: Most common cIRAEs in our study were pruritus and maculopapular rash. The incidence of cIRAEs was lower in our Indian cohort compared to that reported in Caucasian cohorts. Development of cutaneous immune-related adverse event in cancer patients on ICI was associated with a longer progression-free-survival and a better objective-response-rate. Thus, cIRAEs may serve as a surrogate marker for better patient outcomes. Mattioli 1885 2023-07-01 /pmc/articles/PMC10412045/ /pubmed/37557151 http://dx.doi.org/10.5826/dpc.1303a127 Text en ©2023 Duraisamy et al. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
spellingShingle Original Article
Duraisamy, Prasanna
Panicker, Vinitha Varghese
Jose, Wesley Mannirathil
Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
title Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
title_full Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
title_fullStr Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
title_full_unstemmed Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
title_short Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
title_sort characterization and prognostic significance of cutaneous immune-related adverse events in indian patients on immune checkpoint inhibitor therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412045/
https://www.ncbi.nlm.nih.gov/pubmed/37557151
http://dx.doi.org/10.5826/dpc.1303a127
work_keys_str_mv AT duraisamyprasanna characterizationandprognosticsignificanceofcutaneousimmunerelatedadverseeventsinindianpatientsonimmunecheckpointinhibitortherapy
AT panickervinithavarghese characterizationandprognosticsignificanceofcutaneousimmunerelatedadverseeventsinindianpatientsonimmunecheckpointinhibitortherapy
AT josewesleymannirathil characterizationandprognosticsignificanceofcutaneousimmunerelatedadverseeventsinindianpatientsonimmunecheckpointinhibitortherapy